81 related articles for article (PubMed ID: 3418201)
1. [Treatment of patients with ovarian carcinoma: experimental and clinical studies].
Kikuchi Y; Kita T; Iwano I; Miyauchi M; Oomori K; Kizawa I; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):933-5. PubMed ID: 3418201
[No Abstract] [Full Text] [Related]
2. [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
Krommer K; Keller G; Csaba I; Garadnay B; Göcze P
Zentralbl Gynakol; 1990; 112(17):1105-10. PubMed ID: 2264421
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of ovarian cancer].
Kato T; Nishimura H
Gan No Rinsho; 1989 Jan; Spec No():392-8. PubMed ID: 2464708
[No Abstract] [Full Text] [Related]
4. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results].
Sevelda P
Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer: what is poor prognosis disease?
Cohen MH
J Clin Oncol; 1990 Jul; 8(7):1287-8. PubMed ID: 2113572
[No Abstract] [Full Text] [Related]
6. [A combination of cyclophosphamide, adriamycin and platinum (CAP) in the treatment of stage III and IV ovarian cancer].
Chylak V; Krusić J; Kolarić K
Jugosl Ginekol Perinatol; 1988; 28(1-2):41-3. PubMed ID: 3398564
[No Abstract] [Full Text] [Related]
7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
8. [Combined chemotherapy including platinum derivatives in the combined treatment of patients with stage-III to -IV ovarian cancer].
Perevodchikova NI; Gorbunova VA; Grigorova TM; Kozachenko VP; Marenich AF
Vestn Akad Med Nauk SSSR; 1986; (5):8-11. PubMed ID: 3755271
[No Abstract] [Full Text] [Related]
9. Role of intervention surgery in stage III-IV epithelial ovarian carcinoma.
Hoogland H; Blijham G; Bron H; Eekhout A; van Geuns H; Haest J; Huiskes H; Kornman J; de Koning Gans H; Lalisang F
Prog Clin Biol Res; 1985; 201():213-5. PubMed ID: 3841592
[No Abstract] [Full Text] [Related]
10. [Treatment of advanced ovarian carcinoma with cyclophosphamide, adriamycin and cisplatin: evaluation of the therapeutic response and analysis of the collateral effects].
Facchini V; Gadducci A; Ceccarelli P; Dell'Arciprete T; Del Bravo B; Bartolini T; Fioretti P
Ann Ostet Ginecol Med Perinat; 1986; 107(6):359-68. PubMed ID: 3566043
[No Abstract] [Full Text] [Related]
11. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
[No Abstract] [Full Text] [Related]
12. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
13. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
[TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
[TBL] [Abstract][Full Text] [Related]
15. [Importance of clinically prognostic factors in the treatment of advanced ovarian carcinoma].
Albrecht M; Goepel E; Simon WE; Trams G
Geburtshilfe Frauenheilkd; 1985 Jul; 45(7):482-7. PubMed ID: 2993094
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of advanced ovarian cancer].
de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
19. [Effects of chemo-immunotherapy of malignant ovarian tumors. Collaborated study with affiliated hospitals].
Ota M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Aug; 37(8):1391-9. PubMed ID: 2995514
[No Abstract] [Full Text] [Related]
20. [Chemotherapy in advanced forms of carcinoma of the ovary].
Calciati A; Clerico M; Donadio M; Giaccone G
Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
